Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Triazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | PTAFR | P25105 | 8/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | BRD4 | O60885 | 2/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triazolam SCHEMBL29382425 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29228 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29368430 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29349744 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL27600059 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL9055695 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL3262516 | 0.93 | GABRA1 (0.86) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL13352295 | 0.91 | GABRA1 (0.83) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL28059256 | 0.89 | GABRA1 (0.79) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL8274469 | 0.89 | GABRA1 (0.80) | GABRA1GABRA5GABRA2GABRA3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150359773-A1 | COMBINATION METHODS AND COMPOSITIONS INCLUDING SLEEP THERAPEUTICS FOR TREATING MOOD | FEUERSTEIN SETH D (US) | 2015-12-17 | — | — | US | disclosed |
| EP-1539246-A4 | CENTRAL AIRWAY ADMINISTRATION FOR SYSTEMIC DELIVERY OF THERAPEUTICS | BRIGHAM & WOMENS HOSPITAL (US) | 2007-05-16 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1539246-A2 | CENTRAL AIRWAY ADMINISTRATION FOR SYSTEMIC DELIVERY OF THERAPEUTICS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004004798-A2 | CENTRAL AIRWAY ADMINISTRATION FOR SYSTEMIC DELIVERY OF THERAPEUTICS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-01-15 | — | — | WO | disclosed |